Seeking Alpha

Pfizer's (PFE) Inlyta treamtent for advanced kidney cancer "narrowly missed" its primary...

Pfizer's (PFE) Inlyta treamtent for advanced kidney cancer "narrowly missed" its primary endpoint in a Phase III trial of patients who had not yet been treated for the illness. While the drug, also called axitinib, had a median progression-free survival better than that of rival treatment sorafenib, the results weren't statistically significant. Pfizer is now evaluating whether further studies are worthwhile. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs